Massey Cancer Center (2011)

One of the decisive factors in our practice choosing to introduce Calmare Therapy was an independent scientific report published by Thomas J. Smith, MD, Endowed Chair of Palliative Care Research and Medical Director, at Virginia Commonwealth University’s Massey Cancer Center. The 2011 study, one of the first detailed studies conducted in the U. S. since Calmare received FDA clearance, concluded, “Patient-specific cutaneous electrostimulation (the Calmare therapeutic process) with the MC5-A Calmare device appears to dramatically reduce pain in refractory CIPN patients with no toxicity.”

University of Wisconsin Carbone Cancer Center (2011)

A new clinical study at the Carbone Cancer Center at the University of Wisconsin also determined Calmare’s MC-5A scrambler therapy to be “the first known therapy to show measurable results” in helping to alleviate CIPN pain. “This technology has consistently shown very impressive results in our blind study,” reports Toby Campbell, MD, chief of Palliative Medicine, University of Wisconsin.

The American Society of Clinical Oncology (ASCO) June 2012

The American Society of Clinical Oncology (ASCO) completed a clinical trial on the benefits of scrambler therapy to be presented June 1, 2012:

“Scrambler therapy appears to have a promising effect on post herpetic neuropathy (PHN) with prompt and continued relief and no side effects.” PHN is a chronic, painful burning condition affecting nerve fibers and skin.

Background: Post herpetic neuropathy (PHN) is common in cancer and hematologic malignancy patients. It can be debilitating and difficulty to treat effectively. Scrambler therapy, a patient-specific neurocutaneous stimulation device, can be effective in treating chemotherapy induced neuropathy (JPSM 2010) and other neuropathic pain (JPSM 2012).

Results: The patient mean age was 54 ± SD 13 years, 6 men and 4 women, with a mean duration of PHN for 15.6 months (range 2.5 to 48 months) without satisfactory relief despite conventional drugs. The average pain score rapidly diminished from 7.64 ± 1.46 at baseline to 0.42 ± 0.89 at one month, a 95% reduction, with continued relief at 2 and 3 months. Patients achieved maximum pain relief with less than 5 treatments.